Connect with Us
Email Sign Up
Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals is developing QRX003, a topical lotion designed to addres s the underlying mechanisms of Netherton Syndrome. Currently, Quoin is conducting four ongoing investigational studies evaluating QRX003’s safety, efficacy, and potential as the first approved treatment for this devastating condition.
Follow us on:
This website does not provide medical advice and is for educational purposes only.